Drug Type Small molecule drug |
Synonyms TTA |
Target |
Action agonists, inhibitors |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), Lipid peroxidation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H32O2S |
InChIKeyIPBCWPPBAWQYOO-UHFFFAOYSA-N |
CAS Registry2921-20-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tetradecylthioacetic acid | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | Norway | 01 Jan 2002 | |
Dyslipidemias | Phase 2 | Norway | 01 Jan 2002 |
Phase 2 | 16 | Tetradecylthiocetic acid | mkilwlsljc(fsabxbniqr) = ddqsnbtyam cwypvbqemz (hclbvxqebr ) | - | 01 Apr 2009 | ||
Phase 1 | 15 | krqidgcrtu(auaovncrjy) = Transaminase elevations occurred in five pts (33%): 1 gr 1, 1 gr 2 and 3 gr 3- all occurring in month 3 or later. Transaminase elevations resolved after drug discontinuation but recurred with repeated dosing. twjkomkngu (ankvtfaaca ) | - | 20 Jun 2007 |